Obsidian Therapeutics (OBX) Stock Forecast: StockMap's 2-Week Call
OBX stock forecast: StockMap's model makes no two-week call on Obsidian Therapeutics after the Nov 13 close: its evidence is split, 5 reasons for and 9 against. Right in 5 of 6 two-week windows on OBX since Aug 21; by chance, a call on the same dates was right 62% of the time.
Obsidian Therapeutics last closed at $12.56, +0.64% on the session.
Against the IVW growth benchmark the position is +1.55% over the forecast window.
Obsidian Therapeutics' market cap is $775.86M as of November 13, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -18 (too close to call).
Where OBX sits: sized by market cap, coloured by the day's move.
The read is built from 14 underlying insights — 5 bullish and 9 bearish.
Agreement across those insights is 64%.
41 daily calls for OBX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Obsidian Therapeutics in the 100th percentile on valuation and the 11th percentile on return on equity, where 100 is best.
Obsidian Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Obsidian Therapeutics as the 143rd largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.
On that composite Obsidian Therapeutics ranks 165th of 391 in the group, against a group median of -0.24.